retatrutide fat loss clinical trial results Reta data & dosing — a must read (Reta) isn't just another GLP-1. It's a triple-agonist peptide studied in Phase 3 trials for metabolic health — targeting GLP-1, GIP How Does Retatrutide Make You

Metabolic dysfunction-associated steatohepatitis investigations (e.g, ESSENCE, SURVODUTIDE in MASH, and Tirzepatide in MASH), 5

When you eat and drink less, you also take in fewer electrolytes , sodium, potassium, magnesium, and dehydration becomes surprisingly common on GLP-1 medications, especially if you have any vomiting or diarrhea

Acta Diabetol 2017

In March 2026, topline results from the TRANSCEND-T2D-1 trials showed that participants with Type 2 diabetes achieved an average A1C reduction of up to 2.0% and lost nearly 17% of their body weight over 40 weeks

Whilst Ozempic is a glucagon-like peptide-1 (GLP-1) receptor agonist licensed for glycaemic control, there is no established direct link between the drug and increased libido

Please also recommend this newsletter to friends and colleagues - its free